Dr. Gadgeel began his studies at the Grant Medical College and J.J. Group of Hospitals at the University of Bombay and graduated from the University of Mumbai Medical School in 1992. Dr. Gadgeel moved to the United States after that to complete his residency and fellowship, both at the Wayne State University. Dr. Shirish Gadgeel is a practicing lung cancer specialist and team leader of the oncology department at the Barbara Ann Karmanos Cancer Institute, with a keen interest in the treatment of mesothelioma, among a variety of other types of cancers that affect the lungs. Dr. Gadgeel is three times board certified, in hematology, medical oncology and internal medicine.
Grant Medical College and J.J. Group of Hospitals at the University of Bombay
University Of Mumbai - 1992
Wayne State University
Wayne State University
American Board of Internal Medicine
American Board of Internal Medicine - Hematology
American Board of Internal Medicine - Oncology
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
Dr Alice T Shaw, MDcorrespondencePress enter key for correspondence informationemailPress enter key to Email the author, Leena Gandhi, MD, Prof Shirish Gadgeel, MD, Gregory J Riely, MD, Jeremy Cetnar, MD, Howard West, MD, D Ross Camidge, MD, Prof Mark A Socinski, MD, Alberto Chiappori, MD, Tarek Mekhail, MD, Bo H Chao, MD, Hossein Borghaei, DO, Kathryn A Gold, MD, Ali Zeaiter, MD, Walter Bordogna, PhD, Bogdana Balas, MD, Oscar Puig, PhD, Volkmar Henschel, PhD, Prof Sai-Hong Ignatius Ou, MD on behalf of the study investigatorsSee more >>
Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002J...
Gadgeel SM1, Gandhi L2, Riely GJ3, Chiappori AA4, West HL5, Azada MC6, Morcos PN7, Lee RM7, Garcia L8, Yu L7, Boisserie F7, Di Laurenzio L7, Golding S7, Sato J9, Yokoyama S9, Tanaka T9, Ou SH10.See more >>
Evaluation of Antitumor Activity Using Change in Tumor Size of the Survivin Antisense Oligonucleotide LY2181308 in Combination with Docetaxel for Second-Line Treatment...
Natale R1, Blackhall F, Kowalski D, Ramlau R, Bepler G, Grossi F, Lerchenmüller C, Pinder-Schenck M, Mezger J, Danson S, Gadgeel SM, Summers Y, Callies S, André V, Das M, Lahn M, Talbot D.See more >>
Glucocorticoid receptor status is a principal determinant of variability in the sensitivity of non-small-cell lung cancer cells to pemetrexed.
Patki M1, Gadgeel S, Huang Y, McFall T, Shields AF, Matherly LH, Bepler G, Ratnam M.See more >>
American Society of Clinical Oncology
Southwestern Oncology Group
Verified Patient ReviewsRate This Doctor
April 21, 2013
by Michele Polce
“Dr. Gadgeel really cares about his patients. He goes beyond and always knows the next step of the treatment. He treats me as a person not just a patient. He talks with me and calms me down when I’m waiting for the test results. He also cares about my family, because we are all in this together. I have been his patient for almost 3 years and I recommend him to anyone who needs a doctor. He is never rushes me when I have an appointment and he always makes me feel like I’m his only patient that day. ”
July 19, 2015
by Nancy K.
“Dr. Gadgeel is a compassionate doctor. He spends extra time and answers all your questions. I personally recommend you to visit him for lung cancer treatment. ”
December 04, 2009
by Sally G.
“After my very first consultation I knew that Dr. Gadgeel was the right doctor for me. I respect him and his hard working staff.”
September 22, 2009
by Kelly R.
“I can’t tell in words how great Dr. Gadgeel is. He is a caring compassionate doctor and also very honest. If someone depends on him, he will do anything to help that person. He did more for my family member that anyone else. God bless you Dr. Gadgeel. ”
April 28, 2009
by Chris P.
“We had Dr. Gadgeel for a second opinion and we were so impressed of his vast knowledge. ”